HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Sorel, N. Articles by Chomel, J.-C. Search for Related Content PubMed PubMed Citation Articles by Sorel, N. Articles by Chomel, J.-C. Related Collections Molecular Diagnostics and Genetics

Double-Gradient–Denaturing-Gradient Gel Electrophoresis for Mutation Screening of the BCR-ABL Tyrosine Kinase Domain in Chronic Myeloid Leukemia Patients

Laboratoire d’Hématologie et EA 3805, CHU de Poitiers, France;

^aaddress correspondence to this author at: Laboratoire d’Hématologie, CHU de Poitiers, 2 rue de la Milétrie, 86021 Poitiers Cedex, France; fax 335-49444095, e-mail j.c.chomel@chu-poitiers.fr

The first 300 words of the full text of this article appear below.

Chronic myeloid leukemia (CML) is a rare hematopoietic stem cell disorder characterized by the t(9;22) translocation. This somatic event leads to the formation of the BCR-ABL fusion gene, which is translated in a functional protein (1). The Bcr-Abl oncoprotein differs from the endogenous c-Abl protein in both its subcellular localization and its tyrosine kinase (TK) activity. The deregulated Abl TK activity of the Bcr-Abl protein initiates the oncogenic process and represents a target to TK inhibitors.

Among a series of compounds exhibiting TK inhibition, STI 571 (imatinib) was found to be highly effective against Abl and its derivative Bcr-Abl (2)(3). This molecule targets the inactive conformation of the kinase, which leads to stabilization of the protein in its inactive form and impairs ATP binding (4). Approved for the treatment of CML, imatinib induces hematologic and cytogenetic remissions in the chronic phase as well as in the blast phase (5)(6)(7).

A significant proportion of patients, however, become resistant to the treatment. Different mechanisms of imatinib resistance have been described, in particular point mutations within the sequence of the BCR-ABL gene coding for the TK domain (8)(9)(10). Approximately 30 missense mutations have been identified in CML patients. Within the Bcr-Abl TK domain, these mutations are located in the nucleotide binding loop (P-loop), in the active site (imatinib contact site), or in the activation loop (A-loop; Fig. 1A ). Among these mutations, some prevent the binding of imatinib, and others make this binding more difficult. In the latter case, a dose increase can overcome the resistance. Recently, a novel TK inhibitor was described (11). In vitro, this molecule remains active for the majority of Bcr-Abl mutants, with the exception of T315I.

View larger version (38K): [in this window] [in a new window]   Figure 1. . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF]

				T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica, February 1, 2008; 93(2): 186 - 192. [Abstract] [Full Text] [PDF]

				N. Sorel, L. Roy, G. Martineau, F. Guilhot, A. G. Turhan, and J.-C. Chomel Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML. Blood, September 1, 2006; 108(5): 1782 - 1783. [Full Text] [PDF]

				T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood, July 1, 2006; 108(1): 28 - 37. [Abstract] [Full Text] [PDF]